FIFA, May 15 / PRNewswire-FirstCall-Asianet /-- East China Pharmaceutical announced that the application for new drug clinical trial (IND) of HDM1002 tablets declared by the wholly-owned subsidiary of China, the United States and East China was approved by the FDA of the United States and agreed to carry out phase I clinical trials.